Clinical Efficacy and Safety of Thai Herbal Formulation-6 in the Treatment of Symptomatic Osteoarthritis of the Knee: A Randomized-Controlled Trial

Table 2

Efficacy outcome assessments.

	THF-6	Diclofenac	Mean difference	(95% CI)	value^a
Mean change of VAS pain (mm)
MITT analysis	−26.31 ± 16.93	−27.16 ± 18.14	0.86	(−4.39 to 6.10)	0.748
PP analysis	−26.05 ± 17.38	−28.03 ± 17.58	1.98	(−3.61 to 7.56)	0.486
Mean change of VAS stiffness (mm)
MITT analysis	−22.52 ± 17.70	−23.26 ± 19.12	0.74	(−4.77 to 6.25)	0.791
PP analysis	−22.53 ± 17.82	−23.28 ± 18.10	0.75	(−4.98 to 6.49)	0.795
Mean change of SCT (sec)
MITT analysis	−3.35 ± 3.55	−3.42 ± 4.33	0.07	(−1.12 to 1.26)	0.148
PP analysis	−3.44 ± 3.61	−3.27 ± 4.09	−0.17	(−1.40 to 1.06)	0.786
Mean change of KOOS pain
MITT analysis	14.88 ± 14.98	15.77 ± 15.89	−0.89	(−5.50 to 3.73)	0.705
PP analysis	15.24 ± 15.29	15.77 ± 14.54	−0.53	(−5.30 to 4.24)	0.827
Mean change of KOOS other symptoms
MITT analysis	12.29 ± 14.92	15.29 ± 16.90	−3.00	(−7.77 to 1.77)	0.216
PP analysis	12.49 ± 15.17	16.01 ± 16.22	−3.53	(−8.54 to 1.49)	0.167
Mean change of KOOS activities of daily living
MITT analysis	13.25 ± 15.22	14.46 ± 17.78	−1.21	(−6.17 to 3.75)	0.640
PP analysis	13.62 ± 15.23	14.05 ± 16.76	−0.44	(−5.55 to 4.67)	0.866
Mean change of KOOS sport and recreation function
MITT analysis	15.18 ± 17.28	18.57 ± 21.23	−3.39	(−9.20 to 2.41)	0.250
PP analysis	15.64 ± 17.48	19.27 ± 21.79	−3.63	(−9.91 to 2.66)	0.256
Mean change of KOOS knee-related quality of life
MITT analysis	8.42 ± 16.23	13.71 ± 19.65	−5.30	(−10.70 to 0.10)	0.054
PP analysis	9.38 ± 16.30	13.95 ± 18.01	−4.56	(−10.05 to 0.92)	0.102

^aStudent's t-test. KOOS, Knee Injury and Osteoarthritis Outcome Score; SCT, 10-step stair climb test; VAS, visual analog scale.